BioCentury
ARTICLE | Company News

Drais, Tacurion, Astellas deal

May 13, 2013 7:00 AM UTC

Astellas and Drais partnered to form virtual company Tacurion to develop and commercialize Astellas' ASP7035 for nocturia. Tacurion will own all rights and assets related to the vasopressin 2 (V2) receptor agonist, which is slated to start Phase II testing next quarter. Astellas, which has an option to acquire Tacurion following the Phase II trial, is eligible for an undisclosed milestone, plus royalties. ...